Table 2.
Rates of loss to follow-up and duration of antiretroviral therapy by regions with and without tracing or linkage data.
| Regions without linkage or tracing | Regions with linkage or tracing | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
||||||||
| Central Africa | East Africa (no tracing) | Southern Africa (no linkage) | West Africa | Asia Pacific | Latin America | North America | East Africa (tracing) | Southern Africa (linkage)* | |
| Loss to follow-up rate (95%-CI) (per 100 person-years) | |||||||||
| < 6 months ART | 7.3 (6.5–8.3) | 27.0 (26.1–27.9) | 14.9 (14.5–15.3) | 21.9 (21.0–22.8) | 18.0 (16.7–19.5) | 13.2 (12.0–14.5) | 16.7 (15.4–18.2) | 53.0 (51.8–54.3) | 29.5 (28.1–31.0) |
| 6–12 months ART | 6.4 (5.6–7.3) | 15.0 (14.2–15.7) | 7.9 (7.5–8.2) | 12.7 (11.9–13.5) | 10.6 (9.5–11.9) | 11.9 (10.7–13.2) | 16.4 (14.9–18.0) | 34.0 (32.9–35.2) | 20.0 (18.7–21.5) |
| ≥ 12 months ART | 5.4 (5.0–5.8) | 9.3 (8.9–9.6) | 6.3 (6.1–6.5) | 10.8 (10.4–11.1) | 10.6 (10.0–11.3) | 13.7 (12.9–14.4) | 15.8 (14.8–16.7) | 23.3 (22.7–23.9) | 17.0 (16.1–17.9) |
|
| |||||||||
| Median years on ART before lost to follow-up (IQR) | |||||||||
| 1.34 (0.55–2.39) | 0.60 (0.19–1.44) | 0.76 (0.21–1.86) | 1.11 (0.39 – 2.54) | 1.17 (0.37–2.32) | 1.46 (0.64–2.34) | 1.07 (0.46–1.95) | 0.68 (0.24–1.52) | 0.63 (0.24–1.44) | |
*
based on patients who could not be linked to the vital registry